Aliases & Classifications for Ischemic Retinopathy

MalaCards integrated aliases for Ischemic Retinopathy:

Name: Ischemic Retinopathy 52

Summaries for Ischemic Retinopathy

MalaCards based summary : Ischemic Retinopathy is related to retinitis and endotheliitis. An important gene associated with Ischemic Retinopathy is PLXND1 (Plexin D1). The drugs Bevacizumab and Ranibizumab have been mentioned in the context of this disorder. Affiliated tissues include endothelial, retina and testes.

Related Diseases for Ischemic Retinopathy

Diseases related to Ischemic Retinopathy via text searches within MalaCards or GeneCards Suite gene sharing:

(show all 22)
id Related Disease Score Top Affiliating Genes
1 retinitis 10.2
2 endotheliitis 9.9
3 hypoxia 9.9
4 megaloblastic anemia 9.7
5 neuronitis 9.7
6 systemic lupus erythematosus 9.6
7 tetralogy of fallot 9.6
8 neurofibromatosis, type 1 9.6
9 oliver syndrome 9.6
10 crohn's disease 9.6
11 hereditary hemorrhagic telangiectasia 9.6
12 adams-oliver syndrome 9.6
13 cerebral artery occlusion 9.6
14 neuroretinitis 9.6
15 open-angle glaucoma 9.6
16 arteriovenous malformation 9.6
17 uveitis 9.6
18 antiphospholipid syndrome 9.6
19 cerebritis 9.6
20 lupus erythematosus 9.6
21 head injury 9.6
22 shaken baby syndrome 9.6

Graphical network of the top 20 diseases related to Ischemic Retinopathy:



Diseases related to Ischemic Retinopathy

Symptoms & Phenotypes for Ischemic Retinopathy

Drugs & Therapeutics for Ischemic Retinopathy

Drugs for Ischemic Retinopathy (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 67)
id Name Status Phase Clinical Trials Cas Number PubChem Id
1
Bevacizumab Approved, Investigational Phase 4,Phase 2,Phase 3,Phase 1 216974-75-3
2
Ranibizumab Approved Phase 4,Phase 2,Phase 1 347396-82-1 459903
3 Angiogenesis Inhibitors Phase 4,Phase 2,Phase 3,Phase 1
4 Angiogenesis Modulating Agents Phase 4,Phase 2,Phase 3,Phase 1
5 Immunoglobulins Phase 4
6 Antibodies Phase 4
7
Spironolactone Approved Phase 2, Phase 3 1952-01-7, 52-01-7 5833
8
Eplerenone Approved Phase 2, Phase 3 107724-20-9 150310 443872
9
Triamcinolone Approved, Vet_approved Phase 3 124-94-7 31307
10
Heparin Approved, Investigational Phase 3 9005-49-6 772 46507594
11
Aspirin Approved, Vet_approved Phase 3 50-78-2 2244
12
Dalteparin Approved Phase 3 9005-49-6
13 diuretics Phase 2, Phase 3
14 Mineralocorticoid Receptor Antagonists Phase 2, Phase 3
15 Mineralocorticoids Phase 2, Phase 3
16 Natriuretic Agents Phase 2, Phase 3
17 Hormone Antagonists Phase 2, Phase 3
18 Hormones Phase 2, Phase 3
19 Diuretics, Potassium Sparing Phase 2, Phase 3
20 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 2, Phase 3
21 triamcinolone acetonide Phase 3
22 glucocorticoids Phase 3
23 Triamcinolone diacetate Phase 3
24 Triamcinolone hexacetonide Phase 3
25 Peripheral Nervous System Agents Phase 3,Phase 2
26 Immunosuppressive Agents Phase 3
27 Anti-Inflammatory Agents Phase 3
28 insulin Phase 2, Phase 3
29 Insulin, Globin Zinc Phase 2, Phase 3
30 calcium heparin Phase 3
31 Analgesics Phase 3
32 Fibrinolytic Agents Phase 3
33 Cyclooxygenase Inhibitors Phase 3
34 Analgesics, Non-Narcotic Phase 3
35 Heparin, Low-Molecular-Weight Phase 3
36 Platelet Aggregation Inhibitors Phase 3
37 Anticoagulants Phase 3
38 Anti-Inflammatory Agents, Non-Steroidal Phase 3
39 Antipyretics Phase 3
40 Antirheumatic Agents Phase 3
41
Propranolol Approved, Investigational Phase 1, Phase 2 525-66-6 4946
42
Papaverine Approved Phase 2 61-25-6, 58-74-2 4680
43
Tretinoin Approved, Investigational, Nutraceutical Phase 2 302-79-4 5538
44 Moxaverine Investigational Phase 2 10539-19-2
45 Epoetin alfa Phase 1, Phase 2 113427-24-0
46 Hematinics Phase 1, Phase 2
47 Pharmaceutical Solutions Phase 1, Phase 2
48 Antihypertensive Agents Phase 1, Phase 2
49 Adrenergic Agents Phase 1, Phase 2
50 Adrenergic Antagonists Phase 1, Phase 2

Interventional clinical trials:

(show top 50) (show all 57)

id Name Status NCT ID Phase Drugs
1 Bevacizumab and Peripheral Retinal Changes on Wide Field Angiography in Diabetic Macular Edema Unknown status NCT02096874 Phase 4 Bevacizumab
2 Intravitreal Macugen for Ischaemic Diabetic Macular Oedema Completed NCT01175070 Phase 4 Intravitreal injection of pegaptanib sodium
3 Widefield Angiography Guided Targeted-retinal Photocoagulation Combined With Anti VEgf Intravitreal Injections for the Treatment of Ischemic Central Retinal Vein Occlusion, Hemi Retinal Vein Occlusion, and Branch Retinal Vein Occlusion Completed NCT01710839 Phase 4 0.5mg Ranibizumab
4 Laser Therapy Combined With Intravitreal Aflibercept vs Intravitreal Aflibercept Monotherapy (LADAMO) Recruiting NCT02432547 Phase 4 Aflibercept
5 Evaluation of the Effect of Intravitreal Injections of Anti-VEGF on Macular Perfusion in Diabetic Patients Using OCTA Recruiting NCT03246152 Phase 4 Bevacizumab
6 Aflibercept anD navigateD vErsus coNvensional Laser in Diabetic macUlar edeMa Recruiting NCT02554747 Phase 4
7 Peripheral and Macular Retinal Vascular Perfusion and Leakage in DME and RVO Active, not recruiting NCT02503540 Phase 4 Aflibercept
8 Evaluation of the "Treat-and-extend" Scheme in Patients With Retinal Vein Occlusion (RVO) With and Without LASER Treatment of Ischaemic Retinal Areas Not yet recruiting NCT02522897 Phase 4 Ranibizumab
9 A Study of the Beneficial Effects of Eplerenone on Central Serous Chorioretinopathy Unknown status NCT02215330 Phase 2, Phase 3 Eplerenone;Maltodextrin
10 Intravitreal Bevacizumab for Diabetic Retinopathy Completed NCT00600262 Phase 2, Phase 3 intravitreal bevacizumab
11 Combined Triple Therapy in Diabetic Retinopathy (DRP) Completed NCT00806169 Phase 3 triamcinolone and bevacizumab
12 Central Vein Occlusion Study (CVOS) Completed NCT00000131 Phase 3
13 The Swedish Study on Paleolithic Diet for Type 2 Diabetes Recruiting NCT01999452 Phase 3
14 The Individually Marked Panretinal lasEr phoTokoagUlation for Proliferative Diabetic Retinopathy Study - DETECT Active, not recruiting NCT02157350 Phase 3
15 Trial of Aganirsen in iCRVO Patients at Risk of Developing NVG Not yet recruiting NCT02947867 Phase 2, Phase 3 aganirsen
16 Parnaparin vs Aspirin in the Treatment of Retinal Vein Occlusion Terminated NCT00732927 Phase 3 parnaparin;aspirin
17 Comparison of Two Laser Therapy Methods for PDR Unknown status NCT01232179 Phase 2
18 Recombinant Erythropoietin for Neuroprotection in Very Preterm Infants Unknown status NCT00910234 Phase 1, Phase 2 recombinant human erythropoietin (rhEpo);recombinant human erythropoietin (rhEpo);Normal saline
19 Oral Propranolol Versus Placebo for Early Stages of Retinopathy of Prematurity: A Randomized and Prospective Study Completed NCT01238471 Phase 1, Phase 2 propranolol;sucrose 5%
20 Effects of Moxaverine and Placebo on Ocular Blood Flow Completed NCT00709423 Phase 2 Moxaverine;Moxaverin 150mg;NaCl
21 Study of the Efficacy and Tolerability of Intravitreal Injections of Ranibizumab Compared to Intravitreal Injections of Ranibizumab Combined With Targeted Retinal Photocoagulation to Treat Radiation Retinopathy. Recruiting NCT02222610 Phase 2 0.5 mg ranibizumab
22 Safety and Efficacy of Aflibercept in Proliferative Diabetic Retinopathy. Recruiting NCT02151695 Phase 2 Aflibercept intravitreal injections
23 Efficacy & Safety Trial of Intravitreal Injections Combined With PRP for CSME Secondary to Diabetes Mellitus (DAVE) Active, not recruiting NCT01552408 Phase 1, Phase 2 0.3 mg ranibizumab
24 Ranibizumab Therapy for Non-arteritic Ischemic Optic Neuropathy Completed NCT00561834 Phase 1 ranibizumab
25 Rubeosis Anti-VEGF (RAVE) Trial for Ischemic Central Retinal Vein Occlusion Completed NCT00406471 Phase 1 Ranibizumab (Lucentis)
26 Safety Study of Stem Cells Treatment in Diabetic Foot Ulcers Not yet recruiting NCT01686139 Phase 1
27 Study of 2.0 mg Ranibizumab in Subjects With Ischemic Central Retinal Vein Occlusion (RAVE2) Terminated NCT01225146 Phase 1 ranibizumab
28 Diabetes PRP and OCT Unknown status NCT01928550
29 The Effect of Hyperbaric Chamber Treatment on Patients With Diabetic Retinopathy Unknown status NCT02235935
30 Ocular Blood Flow in Early Glaucoma Patients Before and After Treatment With Dorzolamide Unknown status NCT00152932 Dorzolamide 2% drops
31 Prospective Study Phase: Retinal Oxygen Saturation, Blood Flow, Vascular Function and High Resolution Morphometric Imaging in the Living Human Eye Unknown status NCT01348672
32 Retinal Oximtery Following Treatment for Diabetic Maculopathy Unknown status NCT01549132
33 MoCa Test for the Early Detection of Mild Cognitive Impairment During Annual Assessment of Young Adults With Diabetes and in a Control Group Without Diabetes Unknown status NCT02545062
34 Optical Coherence Tomography (OCT) in Retinal Vasculitis Unknown status NCT01998464
35 Study to Evaluate the Effects of Ranibizumab (Lucentis) for Patients With Rubeosis and Neovascular Glaucoma Completed NCT01370135 0.5mg intraocular Ranibizumab (Lucentis)
36 Clinical and Pathophysiological Description of Ocular Ischemic Syndrome Completed NCT00403195
37 Phenotypes of Nonproliferative Diabetic Retinopathy in DM 2 Patients Identified by OCT, CFP, RLA and mfERG (DIAMARKER) Completed NCT01440660
38 Transcorneal Electrical Stimulation Therapy for Retinal Disease Completed NCT00804102
39 Retinal Arteriolar Abnormalities and CV Mortality Completed NCT00011167
40 Clinical Evaluation of Noninvasive OCT Angiography Using a Zeiss OCT Prototype to Compare to Fluorescein Angiography Completed NCT02391558
41 Sickle Cell Disease and Endothelial Progenitor Cells (EPCs) Completed NCT00783627
42 Reflectometric Measurement of Retinal Oxygen Saturation in Patients With Chronic Obstructive Pulmonary Disease (COPD) Grade IV and Healthy Subjects Completed NCT00999024
43 Retinal Ischemia in Central Retinal Vein Occlusion, and the Effects of Treatment With Intravitreal Ranibizumab Completed NCT01360385
44 Correlation Between Macular Ischemia and Peripheral Ischemia in Patients With Diabetes Recruiting NCT02876744
45 Rapid, Non-invasive, Regional Functional Imaging of the Retina. (Diabetic Retinopathy Diagnosis Device) Recruiting NCT01546766
46 Diabetic Retinopathy Assessed by Ultra-wide Recruiting NCT03157206
47 A Systematic Study of Retinal Structure and Function in Diabetic Macular Oedema Recruiting NCT02876393
48 Safety and Effectiveness Study of 532nm Laser Subthreshold Panretinal Photocoagulation for Severe NPDR Recruiting NCT01759121
49 Stem Cell Ophthalmology Treatment Study II Recruiting NCT03011541
50 Effect of Intravitreal Bone Marrow Stem Cells on Ischemic Retinopathy Active, not recruiting NCT01518842

Search NIH Clinical Center for Ischemic Retinopathy

Genetic Tests for Ischemic Retinopathy

Anatomical Context for Ischemic Retinopathy

MalaCards organs/tissues related to Ischemic Retinopathy:

39
Endothelial, Retina, Testes, Bone, Thyroid, Bone Marrow, Eye

Publications for Ischemic Retinopathy

Articles related to Ischemic Retinopathy:

(show top 50) (show all 79)
id Title Authors Year
1
Interplay between CCN1 and Wnt5a in endothelial cells and pericytes determines the angiogenic outcome in a model of ischemic retinopathy. ( 28469167 )
2017
2
Inhibition or deletion of 11I^-HSD1 does not increase angiogenesis in ischemic retinopathy. ( 28089372 )
2017
3
Impact of minocycline on vascularization and visual function in an immature mouse model of ischemic retinopathy. ( 28790417 )
2017
4
MicroRNA-126 Reduces Blood-Retina Barrier Breakdown via the Regulation of VCAM-1 and BCL2L11 in Ischemic Retinopathy. ( 28076855 )
2017
5
Silencing of galectin-1 inhibits retinal neovascularization and ameliorates retinal hypoxia in a murine model of oxygen-induced ischemic retinopathy. ( 28257831 )
2017
6
Intractable Intradialytic Hypotension with Ischemic Retinopathy. ( 27915344 )
2016
7
Evaluation of Nonperfused Retinal Vessels in Ischemic Retinopathy. ( 27661854 )
2016
8
Ischemic retinopathy associated with Crohn's disease. ( 27524921 )
2016
9
Treatment with polyamine oxidase inhibitor reduces microglial activation and limits vascular injury in ischemic retinopathy. ( 27239699 )
2016
10
Global metabolomics reveals metabolic dysregulation in ischemic retinopathy. ( 26617478 )
2016
11
Lack of R-Ras Leads to Increased Vascular Permeability in Ischemic Retinopathy. ( 27654416 )
2016
12
Gemigliptin, a dipeptidyl peptidase-4 inhibitor, inhibits retinal pericyte injury in db/db mice and retinal neovascularization in mice with ischemic retinopathy. ( 26391252 )
2015
13
Epac2-deficiency leads to more severe retinal swelling, glial reactivity and oxidative stress in transient middle cerebral artery occlusion induced ischemic retinopathy. ( 25985753 )
2015
14
A platform of integrative studies from in vitro to in vivo experiments: towards drug development for ischemic retinopathy. ( 25661384 )
2015
15
ISCHEMIC RETINOPATHY IN NEUROFIBROMATOSIS TYPE 1. ( 26252734 )
2015
16
S100A4 gene silencing in oxygen-induced ischemic retinopathy inhibits retinal neovascularization via down-regulation of CREB expression. ( 26358273 )
2015
17
Candesartan stimulates reparative angiogenesis in ischemic retinopathy model: role of hemeoxygenase-1 (HO-1). ( 25420481 )
2015
18
Severe ischemic retinopathy in a patient with systemic lupus erythematosus without antiphospholipid syndrome: A case report. ( 25892939 )
2015
19
Ischemic retinopathy and neovascular proliferation secondary to severe head injury. ( 25143848 )
2014
20
Activation of the Endothelin System Mediates Pathological Angiogenesis during Ischemic Retinopathy. ( 25203536 )
2014
21
Proliferative ischemic retinopathy after arteriovenous malformation embolization in a child with hereditary hemorrhagic telangiectasia. ( 25372443 )
2014
22
Microglia and interleukin-1I^ in ischemic retinopathy elicit microvascular degeneration through neuronal semaphorin-3A. ( 23766263 )
2013
23
Neuronal sirtuin1 mediates retinal vascular regeneration in oxygen-induced ischemic retinopathy. ( 23912262 )
2013
24
Vitreous haemorrhage and ischemic retinopathy in a patient with CADASIL. ( 23064698 )
2013
25
NADPH Oxidase, NOX1, Mediates Vascular Injury in Ischemic Retinopathy. ( 24053718 )
2013
26
Targeting Neovascularization in Ischemic Retinopathy: Recent Advances. ( 25598837 )
2013
27
Angiopoietin-1 guides directional angiogenesis through integrin I+vI^5 signaling for recovery of ischemic retinopathy. ( 24048525 )
2013
28
Macrophage metalloelastase (MMP-12) deficiency mitigates retinal inflammation and pathological angiogenesis in ischemic retinopathy. ( 23285156 )
2012
29
Hypoxia-induced oxidative stress in ischemic retinopathy. ( 23125893 )
2012
30
Endogenous erythropoietin protects neuroretinal function in ischemic retinopathy. ( 22342523 )
2012
31
Overexpression of 15-lipoxygenase-1 in oxygen-induced ischemic retinopathy inhibits retinal neovascularization via downregulation of vascular endothelial growth factor-A expression. ( 23233787 )
2012
32
Peripheral ischemic retinopathy in Adams-Oliver syndrome. ( 22893088 )
2012
33
Zinc transporter 8 (ZnT8) expression is reduced by ischemic insults: a potential therapeutic target to prevent ischemic retinopathy. ( 23209723 )
2012
34
Calpain inhibitors reduce retinal hypoxia in ischemic retinopathy by improving neovascular architecture and functional perfusion. ( 20804843 )
2011
35
Reduced retinal neovascularization, vascular permeability, and apoptosis in ischemic retinopathy in the absence of prolyl hydroxylase-1 due to the prevention of hyperoxia-induced vascular obliteration. ( 21873682 )
2011
36
Differential macrophage polarization promotes tissue remodeling and repair in a model of ischemic retinopathy. ( 22355595 )
2011
37
Increased expression and activity of 12-lipoxygenase in oxygen-induced ischemic retinopathy and proliferative diabetic retinopathy: implications in retinal neovascularization. ( 21228311 )
2011
38
Hyperoxia therapy of pre-proliferative ischemic retinopathy in a mouse model. ( 21705685 )
2011
39
Sema3E-PlexinD1 signaling selectively suppresses disoriented angiogenesis in ischemic retinopathy in mice. ( 21505259 )
2011
40
The matricellular protein cysteine-rich protein 61 (CCN1/Cyr61) enhances physiological adaptation of retinal vessels and reduces pathological neovascularization associated with ischemic retinopathy. ( 21212276 )
2011
41
Outgrowth endothelial cells: characterization and their potential for reversing ischemic retinopathy. ( 20554606 )
2010
42
Moderate GSK-3I^ inhibition improves neovascular architecture, reduces vascular leakage, and reduces retinal hypoxia in a model of ischemic retinopathy. ( 20809259 )
2010
43
Reduced nitro-oxidative stress and neural cell death suggests a protective role for microglial cells in TNFalpha-/- mice in ischemic retinopathy. ( 20107169 )
2010
44
Reversal of ischemic retinopathy following balloon angioplasty of a stenotic ophthalmic artery. ( 20418775 )
2010
45
Early intervention of tyrosine nitration prevents vaso-obliteration and neovascularization in ischemic retinopathy. ( 19815813 )
2010
46
Retinal vascular repair and neovascularization are not dependent on CX3CR1 signaling in a model of ischemic retinopathy. ( 19176215 )
2009
47
Stimulating angiogenesis to prevent ischemic retinopathy. ( 19729095 )
2009
48
Vascular endothelial growth factor upregulates expression of annexin A2 in vitro and in a mouse model of ischemic retinopathy. ( 19536308 )
2009
49
Effects of intravitreal morphine administered at different time points after reperfusion in a rabbit model of ischemic retinopathy. ( 18854781 )
2009
50
MCP-1 deficiency delays regression of pathologic retinal neovascularization in a model of ischemic retinopathy. ( 18487365 )
2008

Variations for Ischemic Retinopathy

Expression for Ischemic Retinopathy

Search GEO for disease gene expression data for Ischemic Retinopathy.

Pathways for Ischemic Retinopathy

GO Terms for Ischemic Retinopathy

Sources for Ischemic Retinopathy

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 MedGen
42 MeSH
43 MESH via Orphanet
44 MGI
46 NCI
47 NCIt
48 NDF-RT
51 NINDS
52 Novoseek
54 OMIM
55 OMIM via Orphanet
59 PubMed
60 QIAGEN
65 SNOMED-CT via HPO
66 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....